Background : This study was designed to evaluate the safety and clinical benefits of a glycoprotein IIb/IIIa receptor inhibitor, ReoPro짰 in the elderly with acute myocardial infarction (AMI) (>70 years of age) undergoing percutaneous coronary intervention (PCI). Methods : AMI patients who underwent PCI with use of ReoPro짰 at Chonnam National University Hospital from Jan 2000 to Jan 2002 were divided into two groups: Group I (>70 years of age: 74짹2.4 years, n=28] and Group II (<70 years of age: 56짹8.0 years, n=122). Early and long-term clinical outcomes after PCI were analyzed in a retrospective fashion. Results : As for risk factors and angiographic profiles, there were no differences between the two groups. Stenting was performed in 18 patients (64%) in group I and in 78 patients (63%) in group II. The incidence of gastrointestinal bleeding was 3 patients in group I and no patient in group II (p=0.005). At one-month evaluation, three cardiac deaths developed in group I, but no cardiac death in group II (p=0.005). During a period of 25짹10.4 months of clinical follow-up, three cardiac deaths (11%) occurred in group I and 3 (2%) in group II, four AMIs (3%) in group II, and one stroke (0.8%) in group II. Target lesion revascularization (TLR) was performed in two patients (7%) in group I and in 24 patients (19%) in group II. No differences were found in the incidences of these variables between the two groups. Conclusion : ReoPro짰 in elderly patients with AMI undergoing PCI entailed higher bleeding complications and early mortality. However, it has comparable clinical effect in elderly patients to younger patients during long-term clinical follow-up.